Johnson & Johnson Raises Full-Year Guidance After Q3 Results
Johnson & Johnson reported Q3 adjusted earnings of $2.59 per share and sales of $25.39 billion, then raised its full-year adjusted earnings outlook to $11.05-$11.15 per share and sales outlook to $101 billion-$101.40 billion.
Johnson & Johnson (NYSE: JNJ) reported stronger-than-expected third-quarter results Tuesday and raised its full-year outlook. 53. 25 billion consensus. 1%.
08 consensus estimate. 29 billion. Chairman and Chief Executive Officer Joaquin Duato said the company’s third-quarter performance and increased sequential growth reflected momentum in its focused portfolio. He said Johnson & Johnson advanced patient-care breakthroughs in the quarter, including the OTTAVA MedTech innovation and positive Phase 3 results in multiple myeloma.
51 on Wednesday. Following the earnings announcement, RBC Capital analyst Trung Huynh kept an Outperform rating and lowered his price target from $290 to $280. Wells Fargo analyst Larry Biegelsen maintained an Overweight rating and reduced his target from $282 to $275.